167 related articles for article (PubMed ID: 8263554)
1. Muscle disease, HIV and zidovudine: the spectrum of muscle disease in HIV-infected individuals treated with zidovudine.
Manji H; Harrison MJ; Round JM; Jones DA; Connolly S; Fowler CJ; Williams I; Weller IV
J Neurol; 1993 Sep; 240(8):479-88. PubMed ID: 8263554
[TBL] [Abstract][Full Text] [Related]
2. Myopathies associated with human immunodeficiency virus and zidovudine: can their effects be distinguished?
Simpson DM; Citak KA; Godfrey E; Godbold J; Wolfe DE
Neurology; 1993 May; 43(5):971-6. PubMed ID: 8492955
[TBL] [Abstract][Full Text] [Related]
3. Mitochondrial myopathy caused by long-term zidovudine therapy.
Dalakas MC; Illa I; Pezeshkpour GH; Laukaitis JP; Cohen B; Griffin JL
N Engl J Med; 1990 Apr; 322(16):1098-105. PubMed ID: 2320079
[TBL] [Abstract][Full Text] [Related]
4. Early features of zidovudine-associated myopathy: histopathological findings and clinical correlations.
Cupler EJ; Danon MJ; Jay C; Hench K; Ropka M; Dalakas MC
Acta Neuropathol; 1995; 90(1):1-6. PubMed ID: 7572071
[TBL] [Abstract][Full Text] [Related]
5. Prognosis in AZT myopathy.
Chalmers AC; Greco CM; Miller RG
Neurology; 1991 Aug; 41(8):1181-4. PubMed ID: 1714057
[TBL] [Abstract][Full Text] [Related]
6. Clinical experience with zidovudine for patients with acquired immune deficiency syndrome and acquired immune deficiency syndrome-related complex.
Pinching AJ; Helbert M; Peddle B; Robinson D; Janes K; Gor D; Jeffries DJ; Stoneham C; Mitchell D; Kocsis AE
J Infect; 1989 Jan; 18 Suppl 1():33-40. PubMed ID: 2521663
[TBL] [Abstract][Full Text] [Related]
7. Analysis of myopathy in a placebo-controlled zidovudine trial.
Simpson DM; Slasor P; Dafni U; Berger J; Fischl MA; Hall C
Muscle Nerve; 1997 Mar; 20(3):382-5. PubMed ID: 9052824
[No Abstract] [Full Text] [Related]
8. Characteristics and pathogenesis of myositis in human immunodeficiency virus infection--distinction from azidothymidine-induced myopathy.
Espinoza LR; Aguilar JL; Espinoza CG; Gresh J; Jara J; Silveira LH; Martinez-Osuna P; Seleznick M
Rheum Dis Clin North Am; 1991 Feb; 17(1):117-29. PubMed ID: 2041882
[TBL] [Abstract][Full Text] [Related]
9. Myopathy in HIV infection: the role of zidovudine and the significance of tubuloreticular inclusions.
Lane RJ; McLean KA; Moss J; Woodrow DF
Neuropathol Appl Neurobiol; 1993 Oct; 19(5):406-13. PubMed ID: 8278024
[TBL] [Abstract][Full Text] [Related]
10. HIV or zidovudine myopathy?
Kieburtz K
Neurology; 1994 Feb; 44(2):361; author reply 362-4. PubMed ID: 8309596
[No Abstract] [Full Text] [Related]
11. Mitochondrial myopathy associated with chronic zidovudine therapy in AIDS.
Peters BS; Winer J; Landon DN; Stotter A; Pinching AJ
Q J Med; 1993 Jan; 86(1):5-15. PubMed ID: 8438050
[TBL] [Abstract][Full Text] [Related]
12. Human immunodeficiency virus type 1 infection and myopathy: clinical relevance of zidovudine therapy.
Grau JM; Masanés F; Pedrol E; Casademont J; Fernández-Solá J; Urbano-Márquez A
Ann Neurol; 1993 Aug; 34(2):206-11. PubMed ID: 8338345
[TBL] [Abstract][Full Text] [Related]
13. [THE VALUE OF MUSCLE BIOPSY IN PATIENTS WITHOUT WEAKNESS, HIGH CREATINE KINASE OR MYOPATHY ON ELECTROMYOGRAPHY].
Dori A; Shelestovich N; Gayster A; Lebedyev A; Berger Y; Rosin D
Harefuah; 2019 Jun; 158(6):372-377. PubMed ID: 31215189
[TBL] [Abstract][Full Text] [Related]
14. Zidovudine-induced mitochondrial disorder with massive liver steatosis, myopathy, lactic acidosis, and mitochondrial DNA depletion.
Chariot P; Drogou I; de Lacroix-Szmania I; Eliezer-Vanerot MC; Chazaud B; Lombès A; Schaeffer A; Zafrani ES
J Hepatol; 1999 Jan; 30(1):156-60. PubMed ID: 9927163
[TBL] [Abstract][Full Text] [Related]
15. Toxic myopathies: muscle biopsy features.
Scola RH; Pereira ER; Lorenzoni PJ; Werneck LC
Arq Neuropsiquiatr; 2007 Mar; 65(1):82-6. PubMed ID: 17420833
[TBL] [Abstract][Full Text] [Related]
16. Zidovudine--the first year of experience.
Williams I; Gabriel G; Cohen H; Williams P; Tedder RS; Machin S; Weller IV
J Infect; 1989 Jan; 18 Suppl 1():23-31. PubMed ID: 2915140
[No Abstract] [Full Text] [Related]
17. [Myopathy and zidovudine].
Mateo O; Gato A; Ballesteros P; Benito L; Pontes MJ; Esquinas G
Enferm Infecc Microbiol Clin; 1992 Oct; 10(8):474-6. PubMed ID: 1489776
[TBL] [Abstract][Full Text] [Related]
18. Neuropsychological outcome of zidovudine (AZT) treatment of patients with AIDS and AIDS-related complex.
Schmitt FA; Bigley JW; McKinnis R; Logue PE; Evans RW; Drucker JL
N Engl J Med; 1988 Dec; 319(24):1573-8. PubMed ID: 3059187
[TBL] [Abstract][Full Text] [Related]
19. Vesicular changes in the myopathies of AIDS. Ultrastructural observations and their relationship to zidovudine treatment.
Panegyres PK; Papadimitriou JM; Hollingsworth PN; Armstrong JA; Kakulas BA
J Neurol Neurosurg Psychiatry; 1990 Aug; 53(8):649-55. PubMed ID: 2170584
[TBL] [Abstract][Full Text] [Related]
20. Incidence and natural history of Mycobacterium avium-complex infections in patients with advanced human immunodeficiency virus disease treated with zidovudine. The Zidovudine Epidemiology Study Group.
Chaisson RE; Moore RD; Richman DD; Keruly J; Creagh T
Am Rev Respir Dis; 1992 Aug; 146(2):285-9. PubMed ID: 1362634
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
